AFATINIB FOR CHORDOMA: A phase II, single arm, multi-centre trial evaluating the efficacy of Afatinib as first-line or later-line treatment in metastatic or unresectable chordoma

DeFI Study: A randomized, double-blind, placebo-controlled, phase III trial of Nirogacestat versus placebo in adult patients with progressing desmoid tumours/aggressive fibromatosis

E7389-G000-213 (BOLD): A phase I/II single-arm study evaluating the safety and efficacy of Eribulin Mesilate in combination with Irinotecan in children with refractory or recurrent solid tumours

E7080-G000-230 (OLIE): A multicenter, open-label, randomized phase II study to compare the efficacy and safety of Lenvatinib in combination with Ifosfamide and Etoposide versus Ifosfamide and Etoposide in children, adolescents and young adults with relapsed or refractory Osteosarcoma

ESPRIT: ESP1/SARC025 Global Collaboration: A phase I study of a combination of the PARP inhibitor, Niraparib and Temozolomide or Irinotecan in patients with previously treated, incurable Ewing sarcoma

GSK 3377794: Open-label phase Ib/IIa clinical trial to assess the safety, tolerability and antitumor activity of genetically engineered NY-ESO-1 specific (c259) T cells (GSK3377794) in combination with anti-cancer agents including Pembrolizumab in HLA-A2+ participants with NY-ESO-1 and/or LAGE-1a positive relapsed and refractory Synovial Sarcoma

HGUS EORTC 62113: A randomised double-blind phase II study evaluating the role of maintenance Cabozantinib in high grade undifferentiated uterine sarcoma (HGUS) or response to Doxorubicin +/-Ifosfamide or in metastatic first line treatment

ICONIC: Improving outcomes through collaboration in osteosarcoma

IMRISA phase II study of intensity modulated radiotherapy (IMRT) in primary bone and soft tissue sarcoma

INTRIGUE: A phase III, interventional, randomised, multicentre, open-label study of DCC-2618 vs sunitinib in patients with advanced gastrointestinal stromal tumours after treatment with imatinib

Kindred Study: The international sarcoma kindred study: a global multi-site prospective cancer genetics study

KCP-330-020 (SEAL): A phase II/III multicentre, randomised, double-blind study of Selinexor (KPT - 330) verus placebo in patient with advanced unresectable differentiated liposarcoma

RAPPER: Radiogenomics: Assessment of polymorphisms for predicting the effects of radiotherapy

REDUCE (EORTC 1762): Reduced dose-density of denosumab for maintenance therapy of unresectable giant cell tumour of bone: a multicentre phase II study

rEECUr: International randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma

SMPaeds: Stratified medicine paediatrics: genomic characterisation of relapsed paediatric cancers for diagnostics and stratified therapy

SPEARHEAD 1: A phase II single arm open-label clinical trial of ADP-A2M4 SPEAR™ T cells in subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

SSG XXII: A phase III prospective, multi-centre, open-label, 2 arm study for evaluation of 2 durations of adjuvant treatment with the tyrosine kinase inhibitor Imastinib Mesylate of operable gastrointestinal stromal cells tumour (GIST) with a high risk for recurrence

Sometimes there may be other trials open - it is always worth asking your doctor.